Latisse Market

Bimatoprost (CAS 155206-00-1), also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.
Latisse Market contains market size and forecasts of Latisse (Bimatoprost) in global, including the following market information:
Global Latisse (Bimatoprost) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Latisse (Bimatoprost) Market Sales, 2017-2022, 2023-2028, (g)
Global top five Latisse (Bimatoprost) companies in 2021 (%)
The global Latisse (Bimatoprost) market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Below 99.5% Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Latisse (Bimatoprost) include Cayman Pharma, Tecoland Corporation, TCS Group, Changzhou BOHIV, Zhejiang Ausun, Ansion Pharma, Lianmin Biochemical, Chirogate International and Everlight Chemical and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Latisse (Bimatoprost) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Latisse (Bimatoprost) Market, by Purity, 2017-2022, 2023-2028 ($ Millions) & (g)
Global Latisse (Bimatoprost) Market Segment Percentages, by Purity, 2021 (%)

• Below 99.5%
• Other

Global Latisse (Bimatoprost) Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (g)
Global Latisse (Bimatoprost) Market Segment Percentages, by Application, 2021 (%)

• Patented Product
• General Products

Global Latisse (Bimatoprost) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (g)
Global Latisse (Bimatoprost) Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:

• Key companies Latisse (Bimatoprost) revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Latisse (Bimatoprost) revenues share in global market, 2021 (%)
• Key companies Latisse (Bimatoprost) sales in global market, 2017-2022 (Estimated), (g)
• Key companies Latisse (Bimatoprost) sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Cayman Pharma
• Tecoland Corporation
• TCS Group
• Changzhou BOHIV
• Zhejiang Ausun
• Ansion Pharma
• Lianmin Biochemical
• Chirogate International
• Everlight Chemical
• GENTEC